United Therapeutics (UTHR) revenue: $3.2B
United Therapeutics reported $3.2B of revenue for the year ended Dec 31, 2025, up 10.6% from $2.9B a year earlier.
From United Therapeutics's filings with the SEC · Read the filing · UTHR stock page
United Therapeutics revenue by year
#927 of 3,622 US companies by revenue · See the full ranking
| Year ended | Revenue | Change |
|---|---|---|
| Dec 31, 2025 | $3.2B | +11% |
| Dec 31, 2024 | $2.9B | +24% |
| Dec 31, 2023 | $2.3B | +20% |
| Dec 31, 2022 | $1.9B | +15% |
| Dec 31, 2021 | $1.7B | – |
Revenue of similar companies
Companies in the same industry as United Therapeutics, by SEC industry code, with the closest revenue. Each name opens the same page for that company.
| Company | Revenue, latest year | Year ended |
|---|---|---|
| Jazz Pharmaceuticals | $4.3B | Dec 31, 2025 |
| PERRIGO | $4.3B | Dec 31, 2025 |
| Alnylam Pharmaceuticals | $3.7B | Dec 31, 2025 |
| Biomarin Pharmaceutical | $3.2B | Dec 31, 2025 |
| United Therapeutics | $3.2B | Dec 31, 2025 |
| Amneal Pharmaceuticals | $3B | Dec 31, 2025 |
| Royalty Pharma | $2.4B | Dec 31, 2025 |
Questions and answers
What is United Therapeutics's revenue?
United Therapeutics reported $3.2B of revenue for the year ended Dec 31, 2025, up 10.6% from $2.9B a year earlier.
Numbers as reported in United Therapeutics's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology